NYSE:MRKPharmaceuticals
Merck (MRK) Valuation Check After Key Oncology Trial Success And Positive EU Opinion
Merck (MRK) has drawn fresh attention after reporting Phase 3 success for its investigational antibody drug conjugate sacituzumab tirumotecan in advanced or recurrent endometrial cancer, alongside a positive EU regulatory opinion for Keytruda plus Padcev in bladder cancer.
See our latest analysis for Merck.
Merck’s recent oncology wins come after a period where momentum cooled in the past quarter, with the 90 day share price return down 5.22%, yet its 1 year total shareholder return of 54.28%...